Absci Appoints Dr. Andreas Busch to Board of Directors

Absci Appoints Dr. Andreas Busch to Board of Directors

Dr. Busch brings deep operational expertise in drug discovery to Absci’s Board VANCOUVER, Wash., March 21, 2022 (GLOBE NEWSWIRE) — Absci Corporation (Nasdaq: ABSI), the drug and target discovery company harnessing deep learning AI and synthetic biology to expand...
ReForm Biologics Changes Name to Comera Life Sciences

ReForm Biologics Changes Name to Comera Life Sciences

Leading biologics company aims to drive a compassionate new era of advanced, self-administered biologics through proprietary therapeutics and research collaborations WOBURN, Mass., January 27, 2022–(BUSINESS WIRE)–ReForm Biologics, Inc., a company...